our medicinesSave Lives
Ventria Bioscience’s internal therapeutic pipeline is focused on safely improving clinical outcomes in infectious disease and inflammatory disease.
Our Research Partners
Bill & Melinda Gates Foundation
In 2017, Ventria Bioscience received a $4.2 million grant from the Bill & Melinda Gates Foundation to fund development of efficient biomanufacturing for new therapeutics targeting Enterotoxigenic Escherichia coli
Children’s Hospital Colorado and University of Colorado School of Medicine
Ventria Bioscience has been engaged in a multi-year collaboration with the research group of Edwin de Zoeten, MD, PhD (Children’s Hospital Colorado and University of Colorado School of Medicine) to investigate the mechanisms by which Ventria’s lead candidate, VEN120—the principal component of which is lactoferrin—reduces inflammation in preclinical models of inflammatory bowel disease (IBD).
Johns Hopkins School of Medicine
Ventria Bioscience is currently engaged in an active clinical research collaboration with Jeremy Walston, MD, and colleagues at the Johns Hopkins School of Medicine. This Phase 2, randomized, controlled clinical trial, Effects of rhLactoferrin on Chronic Inflammation in the Elderly (ELCIE), is designed to investigate how recombinant human lactoferrin (rhLF) produced and purified from rice grain may improve mobility and memory versus placebo in up to 60 older adults with chronic inflammation.
In collaboration with Dr. Bo Lonnerdal at University of California, Davis and Dr. Nelly Zavaleta at Children’s Hospital in Lima, Peru, Ventria Bioscience sponsored a double-blind, randomized controlled clinical study to investigate the ability of ExpressTec-made breastmilk proteins to reduce symptoms in 140 children with acute diarrhea.
University of Minnesota
Ventria Bioscience has previously collaborated with Jason Baker, MD, MS at the University of Minnesota/Hennepin County Medical Center on a pilot clinical trial, Recombinant Human Lactoferrin to Reduce Immune Activation and Coagulation Among HIV Positive Patients: A pilot study.
Our Blog: In Context
CuraVive, the Next Generation Plant-Based Food Ingredients
New Business Unit Announcement Ventria Bioscience announces the launch of its new business unit, CuraVive. The new subsidiary is solely focused on leading the innovation in plant-based functional food ingredients. CuraVive applies over 20 years of Ventria Bioscience’s plant protein production experience to create high-performance plant-based food ingredients of unmatched quality and safety. CuraVive is […]